DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 19-059/S-017
NDA 18-031/S-031

Wyeth-Ayerst Laboratories
Attention: Ms. Mary Alice Dankulich
170 Radnor Chester Road
St. Davids, PA 19087

Dear Ms. Dankulich:

Please refer to your supplemental new drug applications dated December 12, 2000, and January 16, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Inderide LA (propranolol hydrochloride/ hydrochlorothiazide) 80/50, 120/50, 160/50mg Capsules (NDA 19-059) and Inderide (propranolol hydrochloride/ hydrochlorothiazide) 40/25, 80/ 25mg Tablets (NDA 18-031).

These supplemental new drug applications provide for Special Supplements-Changes Being Effected with Final Printed Labeling with the following revisions:

NDA 19-059/S-017 and 18-031/S-031
WARNINGS/Propranolol Hydrochloride (Inderal®)/Diabetes and Hypoglycemia

1. First paragraph: the phrase "in patients on propranolol" has been added to the end of the last sentence.
2. Second paragraph/Last sentence: "in subjects on propranolol" has been changed to "in patients on propranolol."
3. "Acute increases in blood pressure have occurred after insulin-induced hypoglycemia in patients on propranolol" has been added to the end of this section.

NDA 19-059/S-017
The **PRECAUTIONS/Nursing Mothers** subsection has been changed from:

> "Propranolol and thiazides are excreted in human milk. Caution should be exercised when Inderide LA is administered to nursing women"
>
> To:
>
> **Nursing Mothers**
> **Propranolol Hydrochloride (Inderal®)**
> "Propranolol is excreted in human breast milk. Caution should be exercised when Inderide LA is administered to a nursing woman."
>
> **Hydrochlorothiazide**
> "Thiazides appear in breast milk. If the use of the drug is deemed essential, the patient should stop nursing."

In addition, the following minor editorial changes have been made:

19-059/S-017 and 18-031/S-031

1. "Rx only" replaced Caution: Federal law prohibits dispensing without prescription.
2. Manufacture codes and revision dates were updated.

19-059/S-017

3. The second level subsection headings under **WARNINGS** and **PRECAUTIONS** were changed from **bold** to *italics.*

We have completed the review of these supplemental applications, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the final printed labeling included in your December 12, 2000 and January 16, 2001 submissions. Accordingly, these supplemental applications are approved effective on the date of this letter.

If you have any questions, please call:

Ms. Zelda McDonald
Regulatory Health Project Manager
(301) 594-5333

Sincerely,

{See appended electronic signature page}

Raymond J. Lipicky, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research